業績紹介

2016年 論文

  • Influence of physician years on urological journal publication productivity among Japanese urologists.
    Niwa N, Kikuchi E, Matsumoto K, Miyajima A, Oya M.
    Springerplus. 2016 Nov 29;5(1):2040.
  • Obstructive sleep apnea syndrome should be considered as a cause of nocturia in younger patients without other voiding symptoms.
    Maeda T, Fukunaga K, Nagata H, Haraguchi M, Kikuchi E, Miyajima A, Yamasawa W, Shirahama R, Narita M, Betsuyaku T, Asano K, Oya M.
    Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E241-E245.
  • External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study.
    Tanaka N, Mizuno R, Ito K, Shirotake S, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.
    Eur Urol Focus. 2016 Aug;2(3):303-309.
  • Renal hemorrhage caused by acquired inhibitors to coagulation factors VIII and V in a hemodialysis patient.
    Niwa N, Yoshida T, Mizuno R, Oya M, Hayashi M.
    CEN Case Rep. 2016 Nov;5(2):223-226.
  • Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.
    Tanaka N, Kosaka T, Miyazaki Y, Mikami S, Niwa N, Otsuka Y, Minamishima YA, Mizuno R, Kikuchi E, Miyajima A, Sabe H, Okada Y, Uhlen P, Suematsu M, Oya M.
    JCI Insight. 2016 Nov 3;1(18):e83654.
  • A metastatic castration resistant prostate cancer patient with multiple bone metastases has durable biochemical and radiological response to docetaxel chemotherapy.
    Daimon T, Kosaka T, Oya M.
    Am J Clin Exp Urol. 2016 Sep 20;4(2):28-31.
  • Human Adrenocortical Remodeling Leading to Aldosterone-Producing Cell Cluster Generation.
    Nishimoto K, Seki T, Hayashi Y, Mikami S, Al-Eyd G, Nakagawa K, Morita S, Kosaka T, Oya M, Mitani F, Suematsu M, Kabe Y, Mukai K. Int J Endocrinol. 2016;2016:7834356.
  • Asia prostate cancer study (A-CaP Study) launch symposium.
    Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, Chung BH, Chen CH, Fai NC, Hakim L, Chiong E, Letran J, Umbas R, Suzuki K, Nishimura K, Ong TA, Lojanapiwat B, Wu TL, Kim WJ, Murphy D, Ogawa O, Carroll P, Naito S, Tsukamoto T.
    Prostate Int. 2016 Sep;4(3):88-96.
  • The Preoperative Neutrophil-to-lymphocyte Ratio is a Novel Biomarker for Predicting Worse Clinical Outcomes in Non-muscle Invasive Bladder Cancer Patients with a Previous History of Smoking.
    Ogihara K, Kikuchi E, Yuge K, Yanai Y, Matsumoto K, Miyajima A, Asakura H, Oya M.
    Ann Surg Oncol. 2016 Dec;23(Suppl 5):1039-1047.
  • Urinary pH Levels are Strongly Associated with Bladder Recurrence After Nephroureterectomy in Upper Tract Urothelial Carcinoma Patients with a Smoking History. Ide H, Kikuchi E, Hagiwara M, Hayakawa N, Hongo H, Miyajima A, Oya M. Ann Surg Oncol. 2016 Dec;23(Suppl 5):1029-1038.
  • Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T, Rini BI, Chen Y, Bair AH, Ozono S, Naito S, Akaza H.
    Jpn J Clin Oncol. 2016 Aug 29.
  • Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: A case report and literature review. Morita S, Shinoda K, Tamaki S, Kono H, Asanuma H, Nakagawa K, Oya M.
    J Clin Virol. 2016 Sep;82:133-138.
  • Recent advances in renal cell carcinoma from a pathological point of view.
    Mikami S, Oya M, Mizuno R, Kosaka T, Ishida M, Kuroda N, Nagashima Y, Katsube K, Okada Y.
    Pathol Int. 2016 Sep;66(9):481-90.
  • High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
    Shigeta K, Kosaka T, Kitano S, Yasumizu Y, Miyazaki Y, Mizuno R, Shinojima T, Kikuchi E, Miyajima A, Tanoguchi H, Hasegawa S, Oya M.
    Ann Surg Oncol. 2016 Nov;23(12):4115-4122.
  • Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers.
    Fukumoto K, Kikuchi E, Mikami S, Ogihara K, Matsumoto K, Miyajima A, Oya M.
    Cancer Sci. 2016 Sep;107(9):1338-44.
  • Clinical practice patterns for upper tract urothelial carcinoma: a nationwide survey in Japan.
    Kikuchi E, Oya M.
    Jpn J Clin Oncol. 2016 Aug;46(8):768-74.
  • Technical Improvement Using a Three-Dimensional Video System for Laparoscopic Partial Nephrectomy.
    Komatsuda A, Matsumoto K, Miyajima A, Kaneko G, Mizuno R, Kikuchi E, Oya M.
    Asian Pac J Cancer Prev. 2016;17(5):2475-8.
  • Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.
    Rini BI, Tomita Y, Melichar B, Ueda T, Grunwald V, Fishman MN, Uemura H, Oya M, Bair AH, Andrews GI, Rosbrook B, Jonasch E.
    Clin Genitourin Cancer. 2016 Dec;14(6):499-503.
  • Are the Formulas Used to Estimate Renal Function Adequate for Patients Treated With Cisplatin-Based Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Carcinoma?
    Niwa N, Kikuchi E, Masashi M, Tanaka N, Nishiyama T, Miyajima A, Saito S, Oya M.
    Clin Genitourin Cancer. 2016 Oct;14(5):e501-e507
  • Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases.
    Oya M, Tatsugami K, Kabu K, Adachi M, Ito Y, Akaza H.
    Gan To Kagaku Ryoho. 2016 May;43(5):559-69.
  • Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
    Hagiwara M, Kikuchi E, Kosaka T, Mikami S, Saya H, Oya M.
    Urol Oncol. 2016 Aug;34(8):337.e19-26.
  • Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
    Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, Oya M.
    Clin Genitourin Cancer. 2016 Dec;14(6):e575-e583.
  • The prognostic significance of OCT4 expression in patients with prostate cancer.
    Kosaka T, Mikami S, Yoshimine S, Miyazaki Y, Daimon T, Kikuchi E, Miyajima A, Oya M.
    Hum Pathol. 2016 May;51:1-8.
  • Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
    Tanaka N, Mizuno R, Shirotake S, Ito K, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M.
    Urol Oncol. 2016 Jul;34(7):293.e17-25.
  • Should We Try Antiandrogen Withdrawal in Castration-Resistant Prostate Cancer Patients? Insights From a Retrospective Study.
    Hongo H, Kosaka T, Mizuno R, Ezaki T, Matsumoto K, Morita S, Shinoda K, Shinojima T, Kikuchi E, Miyajima A, Oya M.
    Clin Genitourin Cancer. 2016 Dec;14(6):e569-e573.
  • A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride.
    Maeda T, Kikuchi E, Hasegawa M, Ando T, Matsushima M, Yuge K, Ito Y, Miyajima A, Oya M.
    Aging Male. 2016 Jun;19(2):111-6.
  • Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy.
    Kobayashi H, Kikuchi E, Tanaka N, Shirotake S, Miyazaki Y, Ide H, Obata J, Hoshino K, Matsumoto K, Kaneko G, Hagiwara M, Kosaka T, Oyama M, Nakajima Y, Oya M.
    Jpn J Clin Oncol. 2016 Mar 9. pii: hyw028.
  • A Case of Gemcitabine and Cisplatin Chemotherapy in a Patient With Metastatic Urothelial Carcinoma Receiving Hemodialysis.
    Ezaki T, Matsumoto K, Morita S, Shinoda K, Mizuno R, Kikuchi E, Oya M.
    Clin Genitourin Cancer. 2016 Aug;14(4):e413-6.
  • Impact of novel techniques on minimally invasive adrenal surgery: trends and outcomes from a contemporary international large series in urology.
    Pavan N, Autorino R, Lee H, Porpiglia F, Sun Y, Greco F, Jeff Chueh S, Han DH, Cindolo L, Ferro M, Chen X, Branco A, Fornara P, Liao CH, Miyajima A, Kyriazis I, Puglisi M, Fiori C, Yang B, Fei G, Altieri V, Jeong BC, Berardinelli F, Schips L, De Cobelli O, Chen Z, Haber GP, He Y, Oya M, Liatsikos E, Brandao L, Challacombe B, Kaouk J, Darweesh I.
    World J Urol. 2016 Oct;34(10):1473-9.
  • Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
    Hashimoto S, Mikami S, Sugino H, Yoshikawa A, Hashimoto A, Onodera Y, Furukawa S, Handa H, Oikawa T, Okada Y, Oya M, Sabe H.
    Nat Commun. 2016 Feb 8;7:10656.
  • Color Doppler Ultrasound Evaluation of Ureteral Jet Angle to Detect Vesicoureteral Reflux in Children.
    Asanuma H, Matsui Z, Satoh H, Asai N, Nukui C, Aoki Y, Mizuno R, Oya M.
    J Urol. 2016 Jun;195(6):1877-82.
  • A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.
    Akaza H, Uemura H, Tsukamoto T, Ozono S, Ogawa O, Sakai H, Oya M, Namiki M, Fukasawa S, Yamaguchi A, Uemura H, Ohashi Y, Maeda H, Saito A, Takeda K, Naito S.
    Int J Clin Oncol. 2016 Aug;21(4):773-782.
  • Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guerin.
    Fukumoto K, Kikuchi E, Mikami S, Miyajima A, Oya M.
    BMC Urol. 2016 Jan 19;16:5. doi: 10.1186/s12894-016-0122-1.
  • Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma.
    Obata J, Tanaka N, Mizuno R, Kanao K, Mikami S, Matsumoto K, Kosaka T, Kikuchi E, Jinzaki M, Oya M.
    BJU Int. 2016 Oct;118(4):598-603.
  • Spontaneous Regression of Epstein-Barr Virus-Positive Primary Diffuse Large Cell B-Cell Lymphoma of the Urinary Bladder After the Cessation of Enzalutamide.
    Ogihara K, Kosaka T, Kikuchi E, Hongo H, Mikami S, Oya M.
    Clin Genitourin Cancer. 2016 Apr;14(2):e215-8.
  • Relationship Between Increased Expression of the Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract Urothelial Carcinoma.
    Hattori S, Kikuchi E, Kosaka T, Miyazaki Y, Tanaka N, Miyajima A, Mikami S, Oya M.
    Ann Surg Oncol. 2016 Feb;23(2):663-70.
  • Placebo-Induced Severe Diarrhea in a Patient With Metastatic Castration-Resistant Prostate Cancer Participating in a Double-Blind, Randomized, Phase III International Trial.
    Niwa N, Kosaka T, Oya M.
    Clin Genitourin Cancer. 2016 Apr;14(2):e219-20.
  • Case Report: Nodule Development From Subcapsular Aldosterone-Producing Cell Clusters Causes Hyperaldosteronism.
    Nishimoto K, Seki T, Kurihara I, Yokota K, Omura M, Nishikawa T, Shibata H, Kosaka T, Oya M, Suematsu M, Mukai K.
    J Clin Endocrinol Metab. 2016 Jan;101(1):6-9.
  • Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma.
    Jinzaki M, Kikuchi E, Akita H, Sugiura H, Shinmoto H, Oya M.
    Int J Urol. 2016 Apr;23(4):284-98.
  • Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients.
    Ogihara K, Kikuchi E, Yuge K, Ito Y, Tanaka N, Matsumoto K, Miyajima A, Asakura H, Oya M.
    Ann Surg Oncol. 2016 May;23(5):1752-9.
  • Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy. Matsushima M, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Ohashi T, Mikami S, Miyajima A, Shigematsu N, Oya M.
    Int J Urol. 2016 Mar;23(3):247-52.
  • Syndrome of inappropriate antidiuretic hormone secretion in a patient with castration-resistant prostate cancer treated with enzalutamide. Yanai Y, Matsumoto K, Niwa N, Kosaka T, Kikuchi E, Miyajima A, Ito H, Oya M.
    Acta Oncol. 2016;55(3):399-400. doi: 10.3109/0284186X.2015.1054953. Epub 2015 Jun 16. No abstract available.
業績紹介